MANGOCEUTICALS INC (MGRX)
US56270V1061 - Common Stock
MANGOCEUTICALS INC
NASDAQ:MGRX (11/4/2024, 8:23:13 PM)
After market: 2.32 -0.05 (-2.11%)2.37
+0.11 (+4.87%)
Company Profile
Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The firm has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. The company is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. The company also owns a global patent portfolio of oral solution.
Company Info
MANGOCEUTICALS INC
15110 Dallas Pkwy, Suite 600
Dallas TEXAS
P: 18336264679
Employees: 3
Website: https://www.mangorx.com/
MGRX News
14 days ago - Mangoceuticals, Inc.MangoRx Responds to and Refutes Recent Claims Made by Eli LillyDallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,...
24 days ago - Mangoceuticals, Inc.MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLANDALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,...
a month ago - Mangoceuticals, Inc.MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsDallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,...
a month ago - Mangoceuticals, Inc.MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss TreatmentMangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category Dallas,...
3 months ago - InvestorPlaceMGRX Stock Earnings: Mangoceuticals Reported Results for Q2 2024Mangoceuticals just reported results for the second quarter of 2024.
3 months ago - Mangoceuticals, Inc.MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,...
MGRX Twits
Here you can normally see the latest stock twits on MGRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
